Trials / Completed
CompletedNCT00195754
A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.
The Safety of Divalproex Sodium Extended Release Tablets in Migraine Prophylaxis: An Open-Label Extension Study in Adolescents
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if long-term treatment, up to 1 year, with Depakote ER is safe in the reduction of occurrence of migraine headaches in adolescents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | divalproex sodium |
Timeline
- Start date
- 2004-07-01
- First posted
- 2005-09-20
- Last updated
- 2007-07-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00195754. Inclusion in this directory is not an endorsement.